Mortality Benefit of Rivaroxaban Plus Aspirin in Patien Peripheral Artery Disease

Journal of the American College of Cardiology

78, 14-23

DOI: 10.1016/j.jacc.2021.04.083

Citation Report

#	Article	IF	Citations
1	Antithrombotic Therapy to Reduce Mortality in Patients With Atherosclerosis: 2 Pathways to a Single Goal. Journal of the American College of Cardiology, 2021, 78, 24-26.	12.0	3
2	Prevalence and Clinical Implications of Eligibility Criteria for Prolonged Dual Antithrombotic Therapy in Patients With PEGASUS and COMPASS Phenotypes: Insights From the START-ANTIPLATELET Registry. International Journal of Cardiology, 2021, 345, 7-13.	3.2	47
3	Response To: On Isolated Systolic Hypertension and Combined Antithrombotic Therapy. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 563-564.	1.4	0
4	Combination Anticoagulant or P2Y12 Inhibitor With Low-Dose Aspirin Versus Low-Dose Aspirin Alone in Patients at Risk or With Documented Coronary And/Or Peripheral Artery Disease. Current Medical Research and Opinion, 2022, 38, 27-34.	2.9	2
5	Factor IX(a) Inhibitors: An Updated Patent Review (2003-Present). Expert Opinion on Therapeutic Patents, 2022, 32, 381-400.	4.8	15
6	Effective, Disease-Modifying, Clinical Approaches to Patients With Mild-to-Moderate Hypertriglyceridaemia. Lancet Diabetes and Endocrinology,the, 2022, 10, 142-148.	24.9	24
7	Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA - Journal of the American Medical Association, 2022, 327, 662-675.	37.0	769
8	Long-Term Treatment With the Combination of Rivaroxaban and Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	5.0	20
9	Increased Thrombogenicity Is Associated With Revascularization Outcomes in Patients With Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2022, 76, 513-522.e3.	3.4	1
10	Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 773214.	3.2	9
11	COMPASS Study Results as a Foundation for New Treatment Approach for Neurological Patients. Opinion of the Expert Council of December 18, 2021. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 94-99.	0.9	2
12	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1660-1671.	12.0	56
13	Patients Selected for Dual Pathway Inhibition in Clinical Practice Have Similar Characteristics and Outcomes to Those Included in the COMPASS Randomized Trial: The XATOA Registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 825-836.	5.0	29
14	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. JAMA Cardiology, 2022, 7, 747-759.	16.3	52
15	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation, 2022, 145, 1875-1877.	24.6	8
16	Rivaroxaban and Aspirin vs. Aspirin Alone in Asian Compared With Non-Asian Patients With Chronic Coronary Artery Disease or Peripheral Arterial Disease: The COMPASS Trial. European Heart Journal, 2022, 43, 3542-3552.	14.7	15
17	The Cost-Effectiveness of Rivaroxaban With or Without Aspirin in the COMPASS Trial. European Heart Journal Quality of Care & Clinical Outcomes, 2023, 9, 502-510.	4.9	15
18	A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation, 2022, 146, 1196-1206.	24.6	165

#	Article	IF	Citations
19	Variability in Antithrombotic Therapy After Infrainguinal Lower Extremity Bypass. Annals of Vascular Surgery, 2023, 88, 51-62.	1.8	6
20	High Uric Acid Promotes Atherosclerotic Plaque Instability by Apoptosis Targeted Autophagy. Journal of Atherosclerosis and Thrombosis, 2023, 30, 63645.	3.7	9
21	Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial. JAMA Network Open, 2022, 5, e2243201-e2243201.	10.2	15
22	Role of Cerebral Microbleeds in Acute Ischemic Stroke and Atrial Fibrillation. Journal of Thrombosis and Thrombolysis, 2023, 55, 553-565.	2.2	1
23	Peripheral Vascular Remodeling During Ischemia. Frontiers in Pharmacology, 2022, 13, 1078047.	5.3	12
24	The Presence of Residual Vascular and Adipose Tissue Inflammation on 18F-FDG PET in Patients With Chronic Coronary Artery Disease. Nuclear Medicine and Molecular Imaging, 2023, 57, 117-125.	2.6	2
25	Сахарный диабет 2 типа и микрососудистые осложнения у больных стабильной ишемической болезнью сердца: распространенность, прогноз и выбор антитромботической терапии. Ûžno-Rossijskij žurnal Terapevtičeskoj Praktiki, 2022, 3, 7-24.	0.3	4
26	Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. Journal of the American College of Cardiology, 2023, 81, 771-779.	12.0	81
27	Low-Dose Rivaroxaban: Can Cardiovascular Events Be Reduced?. European Heart Journal Supplements, 2023, 25, C20-C26.	2.9	4
28	Patient and Limb Outcomes 10 Years After Endovascular Revascularization of the Superficial Femoral Artery for Peripheral Artery Disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) Study. Vascular Medicine, 2023, 28, 290-298.	2.3	9
29	Switching From Dual Antiplatelet Therapy With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition With Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Thrombosis and Haemostasis, 2024, 124, 263-273.	4.6	9
30	Correlation Between Blood Cadmium Levels and Platelet Characteristics, as Well as Their Impact on Susceptibility to Coronary Heart Disease: Findings From NHANES 2005–2018 Data. Cardiovascular Toxicology, 2024, 24, 335-344.	3.6	5
31	Efficacy and Safety of Combination Therapy With Low-Dose Rivaroxaban in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2024, 13, 2033.	3.8	1
32	Ischemia-Guided Coronary Revascularization Following Lower-Extremity Revascularization Improves 5-Year Survival of Patients With Chronic Limb-Threatening Ischemia. Journal of Endovascular Therapy, 2026, 33, 155-164.	2.1	5
33	Mortalita u ischemické choroby dolních končetin. Vnitrni Lekarstvi, 2024, 70, 145-150.	0.2	0
34	Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment. Current Cardiology Reports, 2024, 26, 505-520.	4.5	15
35	Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement. Journal of the American College of Cardiology, 2024, 84, 936-952.	12.0	24
36	2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases: Developed by the Task Force on the Management of Peripheral Arterial and Aortic Diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM). European Heart Journal, 2024, 45, 3538-3700.	14.7	1,197

#	Article	IF	Citations
37	Effectiveness of Low-Dose Rivaroxaban in Preventing Recurrent Major Adverse Cardiovascular Events in Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Coronary Artery Disease, 2024, 35, 614.	2.2	3
38	Dual Pathway Inhibition in Patients With Peripheral Artery Disease in Germany. Vasa - European Journal of Vascular Medicine, 2025, 54, 142-149.	2.7	1
39	Evaluating Plasma Vesicle Signatures in Chronic Coronary Artery Disease Patients for Tailored Dual Therapy With Low-Dose Rivaroxaban and Aspirin. Journal of Thrombosis and Haemostasis, 2025, 23, 397-400.	5.0	0
40	Dual Pathway Inhibition in Patients With Coronary Artery Disease (CAD) in Clinical Practice in Germany: Results From the German CAD Subgroup of the XATOA Registry. Clinical Research in Cardiology, 2025, .	3.9	0
41	Clinical Management of Peripheral Arterial Disease in Chronic Kidney Disease—A Comprehensive Review From the European Renal Association CKD-MBD Working Group. CKJ: Clinical Kidney Journal, 2025, 18, sfaf089.	4.8	21
42	Анализ реальной клинической практики ведения пациентов с ишемической болезнью сердца и мультифокальным атеросклерозом. Результаты международного Клинического регистра по изучению популяции пАциентов с выявленным МультифокальныМ Атеросклерозом на территории Российской Федерации и стран Евразии (КАММА) (наблюдение — 12 месяцев). Russian Journal of Cardiology, 2025, 30, 6152.	1.9	2
43	Aspirin Plus Rivaroxaban vs Aspirin Alone: Improvement of Claudication, Limb Pain and Ankle-Brachial Index in Diabetic Peripheral Arterial Disease (PAD) Before Revascularization: A Clinical Randomized Trial. International Cardiovascular Research Journal, 2025, 19, e154736.	0.4	1
44	Comparative Efficacy and Safety of Anticoagulant Therapies in Coronary Artery Disease: A Network Meta-Analysis of Randomized Controlled Trials. BMC Cardiovascular Disorders, 2025, 25, 1-12.	3.3	2
45	Эффективность и безопасность различных режимов многокомпонентной антитромботической терапии у больных с мультифокальным атеросклерозом (исследование реальной клинической практики). Cardiovascular Therapy and Prevention (Russian Federation), 2025, 24, 4346.	1.4	0
46	Dual Pathway Inhibition: Redefining the Secondary Prevention COMPASS in Chronic Coronary Artery Disease. International Journal of Angiology, 2025, .	1.1	0
47	Should the Approach to Pre-Procedural Cardiological Diagnostics in Patients With Peripheral Artery Disease Be Reconsidered? The Prevalence of Coronary Artery Disease in Asymptomatic Patients. Journal of Clinical Medicine, 2025, 14, 8858.	3.8	0
48	Multisite Artery Disease. , 2026, .		0
49	Characteristics and Outcomes of Patients With Diabetes Mellitus Selected for Dual Pathway Inhibition in Clinical Practice: The XATOA Registry. Vascular Medicine, 2026, 31, 493-504.	2.3	0
50	Artériopathie des membres inférieurs chez le patient vivant avec un diabète de type 2 : marqueurs du risque et impact des thérapeutiques. , 0, .		0
51	Peripheral Artery Disease Treatment: Scoping Review With ❁SAIMSARA. , 2026, .		0
52	Efficacy and Safety of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Annals of Medicine and Surgery, 2026, 88, 4437-4447.	1.7	0